At 7.52% CAGR Blood Plasma Derivatives Market Growing 2019 Trends, Size, Investments, Share, Merger, Acquisition,Demand, Key Players, Regional, And Global Industry Forecast To 2023

(Heraldkeepers via Comtex)

Blood Plasma Derivatives Market research future flourishing the new report Blood Plasma Derivatives Market is the data and analysis from worldwide marketplace research mission conducted at some point of the duration indexed above. Due to confidentiality, and the proprietary pastimes of the organization for which the studies turned into conducted this sample record has been changed and in some instances complete sections are closely edited or now not available. The target Blood Plasma Derivatives Market and specific companies analyzed in this report

Market Scenario

Market Research Future (MRFR) predicts that the global blood plasma derivatives market will attain the valuation of USD 58.2 billion by 2023, after reaching USD 30.5 billion in 2016. The market can achieve a CAGR of 7.52% during the forecast period (2017-2023), says MRFR.

Growth Boosters and Key Barriers

Blood plasma refers to blood's liquid component that comprises the extracellular matrix. It plays a big part in maintaining electrolyte as well as osmotic balance, and also helps prevent infection and blood disorders within the body. It contains primarily water coupled with various other components including dissolved proteins, immunoglobulin, clotting factors, glucose, hormones, and electrolytes.

Plasma derivatives can be described as the concentrates of certain proteins that need pooling of plasma from a huge number of donors. It requires over hundred plasma donations to generate enough immunoglobulin to treat an immune deficient patient for at least a year. This factor presents numerous lucrative opportunities for technological advancements for elevating plasma-derived products' production.

FREE Sample [email protected]

Esteemed Players

The esteemed players in the worldwide blood plasma derivatives market include SK Plasma (Korea), Grifols (Germany), Fusion Healthcare (India), and others.

Players like Bain Capital (U.S), Biotest AG (Germany), Octapharma AG (Germany), are also operating in the market.

Latest News

March 2019

GCAM, Inc. has added a set of new blood plasma collection centers in Texas (U.S.) to its existing infrastructure. With these additions, the company now owns 10 plasma donation centers across the country.

Notably, rising demand for plasma derivative based therapies is the key factor driving the blood plasma derivatives market. According to a study published in the Journal of Blood Medicine in 2016, it is found that FIX replacement therapy which includes plasma-derived protein are successful in the reduction of disability, and bleeding from hemophilia B. Based on the prevalence rate, hemophilia and von willebrand disease (VWD) are the most common bleeding disorders in the Middle East and Africa. According to the 2014 Annual Global Survey of World Federation of Hemophilia (WFH),

in 2014 the total population of Egypt was 86,895,099 out of which 5,246 people were living with hemophilia, 513 were living with von willebrand disease, and 1,123 with other bleeding disorders. It is also reported that 4201 cases of hemophilia A were registered and among them 37% were under 4 years.

Boost in demand for blood plasma derivatives has been noted on account of the massive patient pool and the lack of alternative treatments. This is believed to add to the strength of the market to a large extent. To elaborate, there is no definite cure for hemophilia at present, wherein the patient requires a lifelong infusion of plasma-derived products. Other crucial factors that have a hand in the market growth include the surge in disease awareness as well as education, rising commitment to research, and organized network of donor centers. On a different note, the high cost of treatment could act as an obstacle in the market growth.

Market Segmentation

The worldwide blood plasma derivatives market has been segmented on the basis of type, application, and end-users.

The blood plasma derivatives market, depending on the type, covers albumin, anti-thrombin, intravenous immunoglobulin (IVIG), fresh frozen plasma (FFP) and others. Other types include Factor VII, Factor IX, and Alpha 1 proteinase inhibitor concentrate.

With respect to the application, the market caters to Hemophilia A, Hemophilia B, HIV, Hepatitis B, Hepatitis C, Thrombocytosis, and others. Other applications covered by the report are Von Willebrand disease.

End users, as per the report, are hospitals, clinics, diagnostic centers, blood transfusion centers, and others.


Regional Insight

The worldwide blood plasma derivatives market is split into the main regions of Europe, Asia Pacific Middle East & Africa as well as North America.

Experts predict that the North America blood plasma derivatives market will surge at a CAGR of 4.25% in the coming years. The regional market is expected to increase from the value of USD 20 billion in 2016 to USD 35.50 billion by 2023. The region is noted for early approval of plasma derivatives products and rising number of fractionation plants, which works in favor of the market. The mounting awareness level pertaining to the use of plasma derivatives for infectious diseases could be another critical factor boosting the market.

Europe is reckoned to be the second-most profitable market for blood plasma derivatives, expected to rise at a CAGR of 3.8% in the years ahead. Exhaustive research on safe blood transfusion within the healthcare centers and numerous research laboratories are the chief reasons for the lucrative market in the region. In addition to the expanding geriatric population in the region, the rise in awareness about blood & plasma donation is perceived to augur well with the market in the ensuing years.

With the fastest-growth in the global blood plasma derivatives market, Asia Pacific will benefit from the prevalence of life-threatening diseases and the high awareness levels in the region. India has been identified as the strongest contender with the quickest growth rate in the region.

The market in Middle East and Africa is presumed to demonstrate consistent growth. Southern and Eastern Africa note the highest number of HIV cases, which accounts for almost 19 million people. The number of HIV cases are expected to increase rapidly in other parts of Middle East and Africa as well. These factors are expected to elevate the demand for blood plasma derivatives in the region in the years to come.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.


Market Research Future

+1 646 845 9312

Email: [email protected]